Adjuvant treatment with the bacterial lysate (OM-85) improves management of atopic dermatitis: A randomized study.

ABSTRACT:

Background

Environmental factors play a major role on atopic dermatitis (AD) which shows a constant rise in prevalence in western countries over the last decades. The Hygiene Hypothesis suggesting an inverse relationship between incidence of infections and the increase in atopic diseases in these countries, is one of the working hypothesis proposed to explain this trend.

Objective

This study tested the efficacy and safety of oral administration of the bacterial lysate OM-85 (Broncho-Vaxom®, Broncho-Munal®, Ommunal®, Paxoral®, Vaxoral®), in the treatment of established AD in children.

Methods

Children aged 6 months to 7 years, with confirmed AD diagnosis, were randomized in a double-blind, placebo-controlled trial to receive, in addition to conventional treatment with

SUBMITTER: Bodemer C 

PROVIDER: S-EPMC5363804 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature